Health Care Journals | Open Access - Edelweiss | Edelweiss Publications

Clinical Cardiology and Cardiovascular Medicine (ISSN 2639-6807)

Research Article

Prevalence of Hyperuricemia and its Association with Other Cardiovascular Risk Factors in Adult Yemeni People of Sana City

Mohammed Ahmed Bamashmos and Khaled Al-Aghbari

DOI Number:


Published on July, 2019



Hyperuricemia is a metabolic problem that has become increasingly common worldwide over the past several decades. Its prevalence is increased in both advanced and developing countries including Yemen. The aim of this cross sectional study was to investigate the prevalence of hyperuricemia in sample of Yemeni adult individual and its relationship to certain cardiovascular risk factors namely obesity, hypertension, serum glucose, total cholesterol, high serum triglyceride, Low High Density Lipoprotein (HDL-C) and high Low Density Lipoprotein (LDL-C).


A sample of 600 adult Yemeni people aged equal or over 18 years was randomly chosen to represent the population living in Sanaa City during a period of two years from April 2017 to August 2018. All the study groups undergo full clinical history and examination includes measurement of BP and BMI, WC and the following laboratory investigation (FBS, Basal serum uric acid level, total cholesterol, serum TG, HDL and LDL).


The prevalence of hyperuricemia in this study was 8.8% (11,6% male and 6.4% female). The serum uric acid level in this study was significantly correlated with age, Waist Circumference (WC), SBP, DBP, FBS, T-cholesterol, TG and LDL but not with HDL.


There is strong relationship between serum uric acid level and other cardiovascular risk factors.


Hyperurecemia is metabolic problem that has become increasingly worldwide over the past several decades and its the most risk factor for gout [1]. Hyperurecimea is defining as serum urate level greater than 6mg/dl in in women and 7mg/dl in men, above this concentration serum urate supersaturates in body fluid and is prone to crystallization and subsequent deposition in the tissue [2].The association of hyperurecemia and gout with other medical condition such as hypertension, chronic kidney diseases, dyslipidemia and other cardiovascular diseases has been recognized for over 100 years [3]. The prevalence of hyperurecemia has been increased in recent years, not only in advanced countries but also in developing countries along with the development with their economics [4]. Published population-based prevalence data of hyperuricemia were reported in 13 of the 21 Global Burden of Diseases (GBD) regions, and a total of 24 countries. In most part of Asia Hyperuricemia is relatively prevalent, but in East Asia it found to be most prevalent. Lowest percentage is seen in Papua New Guinea 1% and in Marshall Islands 85% is seen.

In japan the high income Asian country Hyperuricemia has increased by five folds in time of two decades. There is no published population-based epidemiological studies on hyperuricemia were identified during the specified systematic review period [5]. Hyperuricemia can be causes by over production of urate which account of less than 10% of the cause such as high cellular turnover, genetic error and tumor lysis syndrome or far more commonly inefficient excretion by the kidney due to renal insufficiency of any cause or medication that impair renal urate clearance [6]. In numerous epidemiological studies since 1950 a positive association has been seen between serum uric acid and cardiovascular diseases such as ischemic heart disease and stroke [7,8].

However weather uric acid is independent risk factor for cardiovascular disease is still disputed as several studies has suggested that hyperurecemia is merely associated with cardiovascular disease because of confounding factors such as obesity, hypertension, dyslipidemia, use of diuretic and insulin resistance [9]. Obesity and central fat distribution were associated with hyperurecemia. Patients with central obesity have greater risk of hyperurecemia [4].

There are many researches was conducted to evaluate the relationship between leptin hormone and the cluster of hyperurecemia in order to identify the pathogenic mechanism associating obesity with hyperurecemia. It was suggested that leptin could be a pathogenic factor responsible for hyperurecemia in obese patients [10]. The strong association between hypertension and hyperurecemia has been recognized for more than century. More than one large epidemiological studies published over the past 7 years have found that serum urate level predict later development of hypertension [11,12].

Experimental studies have reported that hyperurecemia induces systemic hypertension and renal injury via activation of renin angiotensin system and direct intery of uric acid into both endothelial and vascular smooth muscle cells, decreased neuronal nitric oxide synthase in the juxtaglomerular apparatus resulting in local inhibition of endothelial nitric oxide level, stimulation of vascular smooth muscle cell proliferation and stimulation of vasoactive and inflammatory mediators [13,14]. There is strong association between hypertriglycemia and hyperurecemia this association could be explained by insulin resistance as hypertriglyceridemia and hyperurecemia are suggested to be associated with insulin resistance syndrome [15].

The association of hypertriglyceridemia and hyperurecemia in patients with insulin resistance syndrome could be explained by accumulation of glycolytic intermediate and release of free fatty acid from adipose tissue [16]. The resemblance of hyperurecemia and the metabolic syndrome has led to the suggestion that the metabolic syndrome can be further expanded to include hyperurecemia [17]. A prospective study in Korea suggested that higher uric acid concentration predicted the incidence of hypertension and the development of metabolic syndrome and hyperurecemia has been considered as component of metabolic syndrome [18,19].

Material and method

This was across sectional population based study conducted in Sanaa city for a period of 2 years between September 2016 and September 2018 a sample of 600 adult Yemeni people (275 male and 325 female aged ≥ 18 years) was randomly selected from those attending Al-Kuwait University Hospital and Consultation Clinic. All the participants in this study undergo complete clinical history (regarding their age, occupation, habit, any history of hypertension, diabetes mellitus, dyslipidemia and medication) Anthropometric measurement includes measurement of height, weight, waist circumference and systolic and diastolic blood pressure.

Height was measured with tapeline to the nearest.5cm and weight was measured with beam scale balance. Participants wore light clothing and were asked to remove shoes, heavy outer garments Body Mass Index (BMI: kg/m2) was calculated from measured weight and height. BMI was classified as underweight (<18.5 kg/m2), normal (18.5-25 kg/m2), overweight (25-30 kg/m2) and obese (>30 kg/m2) by WHO criteria [20]. Waist circumference was manually measured on standing subjects with soft tape midway between the lowest rib and the iliac crest. Abdominal obesity was defined as WC ≥ 90 cm (male) or WC ≥ 80 cm (female) by IDF consensus [21].

Two blood pressure recording were obtained from the right arm of patients with slandered mercury sphygmomanometer in a sitting position after 10 min. of rest measurement were taken in 3-5 minutes interval and the mean values were calculated. Blood pressure was classified as normotensive (SBP<120 mmHg and DBP<80 mmHg), pre-hypertensive (SBP: 120-139 mmHg and/or DBP: 80-89 mmHg) and hypertensive (SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg) by the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7) [22]. The American Diabetes Association criteria was used to classify FBG as normal glucose (FBG<5.6 mmol/L), Impaired Fasting Glucose (IFG) (FBG ≥ 5.6 mmol/L ≤ FBG<7.0 mmol/L), and diabetic (FBG ≥ 7.0 mmol/L, Serum uric acid were measured [23]. Hyperurecemia is defined as serum uric acid level greater than 6.0mg/|dl in women and 7.0 mg/dl in men. Dyslipidemia was classified according to ATP III, TG: Normal<1.69 mmol/L, Borderline high 1.69-2.26 mmol/L, High 2.26-5.65 mmol/L, Very high ≥ 5.65 mmol/L; TC: Desirable<5.17 mmol/L, Borderline high 5.17-6.24 mmol/L, High ≥ 6.24 mmol/L; HDL-C: High 1.56 mmol/L, Optimal 1.03-1.56 mmol/L, Low

The results were analyzed by using (Social Package of Statistical Science) SPSS V.15 from LEAD Technologies Inc., USA. Basic characteristics of subjects are presented as mean and slandered deviation for quantities variables and as frequency and percent for qualitative variable. The total participants were divided into two groups according to the sex then there were divided into two mean groups according to serum uric acid level. The prevalence of cardiovascular diseases risk factors among two groups were calculated and Chi-square test was used to detect the significance /The mean of uric acid in different categories of separated variable were determined and the comparison between the mean was achieved by independent t-test and one way ANOVA test. The relationships between parameters were examined by calculating persons correlation coefficient. For investigating for most effective factors on hyperurecemia such as blood pressure anthropometrical and biochemical (except UC) measurement were considered for Binary logistic regression P-value less than 0.05 was considered statistically significant.


A study sample includes 600 person aged between 18-83 of them 275 (45.4%) were male and 325 (54.6%) were female. The prevalence of high serum uric acid level in the study group was 53 (8.8%) with no significant difference between male and female (Table 1) regarding the clinical and laboratory parameters in the study group BMI. WS, serum cholesterol, high TG, low high density lipoprotein, high LDL and high FBS were significantly higher in women than in men (17.2%, 35%, 43.3%, 41.2%, 19.3%, 53.8% and 26.4% vs 13.8%, 14.5%, 27.6%. 27.2%, 8.7%, 38.1% and 19.2% respectively, while the BP was significantly higher in men than women, also there was no significant difference between male and female regarding serum uric acid level.


Hyperurecemia is increasingly common medical problem not only in the advanced countries, but also in the developing countries. The incidence of high serum uric acid is increased word wide with average of 20% of population having hyperurecemia and the serum uric acid level is increased with age. It has been described that hyperurecemia is associated with other cardiovascular risk factors such as obesity, dyslipidemia, hyperglycemia and hypertension [1-3]. Elevated serum uric acid levels are commonly seen in association with glucose intolerance, hypertension and dyslipidemia, a cluster of metabolic and hemodynamic disorders which characterize the so-called metabolic syndrome [25-29]. To our knowledge there is no data about the prevalence of hyperurecemia in Yemen so we decided to carry out this research in order to know the prevalence of hyperurecemia and its association with other cardiovascular risk factors in Yemeni population.

Note: SUA-Serum Uric Acid, FBS- Fasting Blood Sugar, IFG- Impaired Fasting Glucose, T.Ch- Total Cholesterol, TG- Triglyceride, HDL- High Density Lipoprotein, LDL- Low Density Lipoprotein.

Table 1: Shows the clinical and laboratory characteristics of the study group.

Table 1: Shows the clinical and laboratory characteristics of the study group.

Note: Table 2 present comparing the mean of selected study parameters in relation to the uric acid level, it shows the mean of age, SBP, WS, fasting blood glucose, total cholesterol, TG and LDL were significantly higher within hyperurecemic study population in comparing to those with normal serum uric acid level, there were no significant difference in DBP, BMI and HDL between the two groups.

Table 2: The prevalence of both clinical and laboratory character of person with high and normal serum uric acid.

Table 2: The prevalence of both clinical and laboratory character of person with high and normal serum uric acid.

Note: Table 3 shows the simple correlation coefficients between serum uric acid levels and the various cardiovascular risk factors in the population. Uric acid was significantly positively correlated with age, SBP, FBS, TG, total cholesterol, LDL (P-value ≤ 0.01) and weak positive correlated with DBP, BMI and WC (P-value ≤ 0.05 ) while it was insignificantly correlated with HDL (P-value 0.411).

Table 3: Shows the correlation between the serum uric acid level and different cardiovascular risk factors.

Table 3: Shows the correlation between the serum uric acid level and different cardiovascular risk factors.

The mean observations of the present study are the following; firstly the prevalence of hyperurecemia present in a good proportion in Yemeni peoples and it was insignificantly high in women than in men. Secondly significant correlation between serum uric acid the various cardiovascular risk factors were found. The prevalence of hyperurecemia in the present study was 8.8%, which is mainly near to that reported in Saudi Arabia (9.3%), Iran (8%), Thailand (9-11%), Mexico (11%) and in Turkish (12%) which may be reflected to similar race and environmental factors. while its lower than that found in Columbia (26.3%).

Indian (25.8%), Taiwan (30.4%) and USA (21-22%) which may be attributed to the high economic state of this countries. Hyperurecemia was insignificantly higher in women (7.9%) than men (6.3%) which may be explained by high prevalence of obesity in women (BMI and WC was 17.2%, 35% in women VS 13.8% and 14.1% in in men respectively. This finding was supported by study done in Saudi Arabia and but other studies are against this observation. Comparing hyperurecemic subject with those with normal serum uric acid level, those with hyperurecemia are older centrally obese, had high systolic blood pressure, high FBS, total cholesterol, triglyceride, and LDL [30-36] (Table 2).

In this study, multiple logistic regression results have further confirmed the association between metabolic abnormalities and high serum uric acid, and have conducted further stratified analysis on each metabolic abnormality-related indicator. Table 3 shows the simple correlation coefficients between serum uric acid levels and the various cardiovascular risk factors in the population. Our results have shown that high serum uric acid was significantly positively correlated with age, SBP, FBS,TG, total cholesterol, LDL (P-value ≤ 0.01) and weak positive correlated with DBP, BMI and WC (P-value ≤ 0.05 ) while it was insignificantly correlated with HDL (P-value 0.411) [35].

Elevation of the serum uric acid level has been known associated with major cardiovascular risk factors, such as hypertension, insulin resistance, dyslipidemia and obesity, which are hallmarks of metabolic syndrome [36-39]. Similar to other studies, in this study, individuals with hyperuricemia had higher prevalence of major cardiovascular risk factors, including dyslipidemia, hypertension and overweight. Uric Acid (UA) is a known endogenous scavenger, which provides a major part of the antioxidant capacity against oxidative and radical injury. However, at high levels, UA can shift from an antioxidant to a pro-oxidant factor (shuttle capacity), depending on the characteristic of the surrounding microenvironment (e.g., UA levels, acidity, depletion of other antioxidants, reduced Nitric Oxide (NO), availability) [40,41].

Accordingly, high UA values have been associated with metabolic syndrome, Cardiovascular Disease (CVD), and renal dysfunction, involving mechanisms that favor oxidative stress, inflammation, and endothelial dysfunction. The result of this study showed significant positive correlation were found between serum uric acid and several component of the metabolic syndrome such as higher WS, BP, TG and FBS (p-value ≤ 0.005) but there was insignificant negative correlation with HDL. Several possible pathophysiological mechanisms have been evoked to explain these associations including insulin resistance, the use of diuretics or impaired renal function accompanying hypertension [42-49].

Indeed the kidney seems to play an important role in the development of the metabolic syndrome. Insulin-resistant individuals secrete larger amounts of insulin in order to maintain an adequate glucose metabolism. The kidney which is not insulin-resistant responds to these high insulin levels by decreasing uric acid clearance, probably linked to insulin-induced urinary sodium retention. Insulin resistance may increase blood pressure directly via enhanced proximal tubular sodium reabsorption or indirectly by the sympatho-adrenal system [43-45]. Thereby, the kidney has been implicated as the potential link between muscle insulin resistance and compensatory hyperinsulinemia and the development of hyperuricemia and eventually hypertension.


Our study demonstrates an alarming high prevalence of hyperurecemia among Yemeni patients that increases the burden on overstrained Yemeni health system with uprising CVDs and other hyperurecemia related health problems e.g. hypertension, dyslipidemia DM. There is also an urgent need to develop strategies for prevention, detection, and treatment of hyperurecemia that could contribute to decreasing the incidence of grave consequences such cardiovascular disease and chronic renal diseases.


1.        Terkeltaub RA. Clinical practice Gout (2003) N Engl Med 349.

2.        Sachs L, Batra LK and Zimmermann B. Medical implication of hyperurecemia (2009) Med Healt Rhode Island 92: 353.

3.        Feig DIU, Kang DH and Johnson RJ. Uric acid and cardiovascular risk (2008) N Engl Med 359: 1811-1821.

4.        Li-ying C, Wen H, Chen Z, Dai H and Ren J. Relationship between hyperurecemia and metabolic syndrome (2007) J Zhejiang University Sci 8: 593-598.

5.        Smith E and March L. Global Prevalence of Hyperuricemia: A Systematic Review of Population-Based Epidemiological Studies (2015) Am collage rheumatol 9.

6.        Andrew J, Luk M and Simkin P. Epidemiology of hyperirecemia and gout (2005) Am collage managed care 11: s435-s442.

7.        Gertler MM, Gam SM and Levine SA. Serum uric acid level in relation to age and physique in health and coronary heart diseases (1951) Ann Intern Med 34: 1421-1431.

8.        Fang J and Alderman MH. Serum uric acid level and cardiovascular mortality; The NHANES 1 epidemiology follow up study 1971-1992 (2000) JAMA 283: 2404-2410.

9.        BurnierM and BrunnerHR. Is hyperurecemia a predictor of cardiovascular risk? (1999) Curr Opin Nephrol Hypertens 8: 167-172.

10.     Fruehwald SB and PetersA, Kern W and Beyer J. Serum leptin is associated with serum uric acid concentrations in humans (1999) Metabolism 48: 677-680.

11.     Perlstein TS, Gumieniak O and Williams GH. Uric acid and the development of hypertension in normotensive aging study (2006) Hypertension 48: 1013-1036.

12.     Krishnan E, Kwoh CK, Schumacher HR and Kuller L. Hyperurecemia and incidence of hypertension among men without metabolic syndrome (2007) Hypertension 49: 298-303.

13.     Mazzali M, Kanellis J, Han L, Feng L, et al. Hyperurecemia induce primary arteeriopathy in rats by a blood pressure independent mechanism (2002) Am J Physiol Renal Physiol 282: F991-F997.

14.     Johnson RJ. Kang DH and Feig D. Is there apathogenetic rule for uric acid in hypertension and cardiovascular and renal diseases (2003) Hypertension.

15.     Bosello E and Zamboni M. Visceral obesity and metabolic syndrome (2000) Obes Rev 1: 47-56.

16.     Leyva F, Wingrove CS and Godsland IF. The glycolytic pathway to coronary herat diseases; ahypothesis (1998) Metabolism 47: 6657-662.

17.     Klein BEK, Klein R and Lee KE. Components of metabolic syndrome and risk of cardiovascular diseases and diabetes in Beaver Mam (2002) Diabetes Care 25: 1790-1794.

18.     Yoo TW, Sung KC, Shin HS, Kim BS, Lee HM, et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome (2005) Circ J 9: 928-933.

19.     Onat A, Uyarel H, Hergenc G, Karabulut A, Albayrak S, et al. Serum uric acid is a determinant of metabolic syndrome in population-based study (2006) Am J Hypertens 19: 1055-1062.

20.     Allison DB, Downey M, Atkinson RL, et al. Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of the Obesity Society (2008) Obesity (Silver Spring) 16: 1161-1177.

21.     Hou X, Lu J, Weng J, Ji L, Shan Z, Liu J, Billington JC, Bray AG, et al. Impact of waist circumference and body mass index on risk of cardio metabolic disorder and cardiovascular disease in Chinese adults: a national diabetes and metabolic disorders survey (2013) PLoS One 8: e57319.

22.     European Society of Hypertension-European Society of Cardiology Guidelines Committee: Guidelines for the management of arterial hypertension (2003) J Hypertens 21: 1011-1053.

23.     American Diabetes Association. Standards of Medical Care in Diabetes-2011 (2011) Diabetes Care 34: S11-S61.

24.     Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) (Adult Treatment Panel III) (2001) JAMA 285: 2486-2497.

25.     Bonora E, Targher G, Zenere MB, Saggiani F, Cacciatori V, et al. Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The verona young men atherosclerosis risk factors study (1996) Int J Obes Relat Metab Disord 20: 975-980.

26.     Zavaroni I, Mazza S, Fantuzzi M, DallAglio E, Bonora E, et al. Changes in insulin and lipid metabolism in males with asymptomatic hyperuricemia (1993) J Intern Med 234: 25-30.

27.     Vuorinen-Markkola H and Yki-Järvinen H. Hyperuricemia and insulin resistance (1994) J Clin Endocrinol Metab 78: 25-29.

28.     Facchini F, Ida Chen Y-D, Hollenbeck CB and Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance and plasma uric acid concentration (1991) JAMA 266: 3008-3011.

29.     Reaven GM. The kidney: an unwilling accomplice in syndrome X (1997) Am J Kidney Dis 30: 928-931.

30.     Al-arfa AS. Hyperurecemia in Saudia Arabia (2001) Rhaumatol Int 20: 61-64.

31.     Smith E and March L. Global Prevalence of Hyperuricemia: A Systematic Review of Population-Based Epidemiological Studies (2015) Arthritis Rheumatol 67.

32.     Sari I, Akar S, Pakoz B and Sisman AR. The prevalence of hyperurecemia in an urban population, Izmer Turkey (2009) Rheumatol Int 29: 869-874.

33.     Lombo B, Melo AA, Benavides J and Lopez M. Prevalence of Hyperuricemia and Cardiovascular Risk Factors in a Population from Colombia (2010) World congress of cardiology, China, 122.

34.     Billa G, Dargad R and Mehta A. The prevalence of hyperurecemia in indian subject attending hyperurecemia screening program -A retrospective study (2018) J the association of phys ind 66.

35.     Qian Yu, Hsi-che Shen, Yi-chun Hu, Yu-fen Chen and Tao-hsin Tung. Prevalence and Metabolic Factors of Hyperuricemia in an Elderly Agricultural and Fishing Population in Taiwan (2017) Arch Rheumatol 32: 149-157.

36.     Masuo K, Kawaguchi H, Mikami H, Ogihara T and Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation (2003) Hypertension 42: 474-480.

37.     Sundström J, Sullivan L, DAgostino RB, Levy D, William B, Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence (2005) Hypertension 45: 28-33.

38.     Li C, Hsieh MC and Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia (2013) Current opinion in rheumatology 25:210-216.

39.     Puig JG and Martinez MA. Hyperuricemia, gout and the metabolic syndrome (2008) Current opinion in rheumatology 20:187-191.

40.     Ames BN, Cathcart R, Schwiers E and Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: A hypothesis (1981) Proc Natl Acad Sci 78: 6858-6862.

41.     Pingitore A, Lima GP, Mastorci F, Quinones A, Iervasi G, Exercise and oxidative stress: Potential effects of antioxidant dietary strategies in sports (2015) Nutrition 31:916-922.

42.     Gliozzi M, Malara N, Muscoli S and Mollace V. The treatmentof hyperuricemia (2015) Int J Cardiol.

43.     Battelli MG, Polito L and Bolognesi A. Xanthine oxidoreductase in atherosclerosis pathogenesis: Not only oxidative stress (2014) Atherosclerosis 237: 562-567.

44.     Billiet L, Doaty S and Katz DJ. Review of hyperurecemia as marker of metabolic syndrome (2014) ISRN Rhaumatology Pp: 1-7.

45.     Reaven GM. The kidney: an unwilling accomplice in syndrome X (1997) Am J Kidney Dis 30: 928-931.

46.     Rathmann W, Funkhouser E, Dyer AR and Roseman JM. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults (1998) Annals Epidemiol 8: 250-261.

47.     Agamah ES, Srinivasan SR, Webber LS and Berenson GS. Serum uric acid and its relations to cardiovascular disease risk factors in children and young adults from a biracial community: The Bogalusa Heart Study (1991) J Lab Clin Med 118: 241-249.

48.     Lee J, Sparrow D, Vokonas PS, Landsberg L and Weiss ST: Uric acid and coronary heart disease risk: evidence for a role of uric acid in the obesity-insulin resistance syndrome. The Normative Aging Study (1995) Am J Epidemiol 142: 288-294.

49.     Bruno G, Cavallo-Perin P, Bargero G, Borra M, Calvi V, Prevalence and risk factors for micro-and macroalbuminuria in an Italian population-based cohort of NIDDM subjects (1996) Diabetes Care 19: 43-47.

*Corresponding author: 

Mohammed Ahmed Bamashmos, Associate Professor of internal medicine and Endocrinology, Sanaa University, Yemen, E-mail:


 Bamashmos AM and Al-Aghbari K. Prevalence of hyperuricemia and its association with other cardiovascular risk factors in adult Yemeni people of Sanaa city (2019) Clinical Cardiol Cardiovascular Med 3: 10-14.


Hyperurecemia, Dyslipidemia, BMI, FBS.